Sierra Oncology Appoints Christina Thomson as General Counsel - Seite 2

Equity Inducement Grant
Sierra Oncology granted an equity award on July 28, 2020 to Christina Thomson as a material inducement to her employment as General Counsel with the Company. The award was approved by the Compensation Committee of the Company’s Board of Directors under Sierra’s 2018 Inducement Plan that is used exclusively for the grant of equity awards as an inducement material to an individual's entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The option will have an exercise price equal to the closing price of Sierra’s common stock on the date of grant. The option will vest and become exercisable as to 25% of the shares on the first anniversary of Ms. Thomson’s start date, and then will vest and become exercisable as to the remaining 75% of the shares in 36 equal monthly installments following the first anniversary, subject to Ms. Thomson’s continued employment with Sierra on such vesting dates. The option is subject to the terms and conditions of Sierra’s 2018 Equity Inducement Plan, and the terms and conditions of the stock option agreement covering the grant.

About Sierra Oncology
Sierra Oncology is a late stage drug development company focused on achieving the successful registration and commercialization of momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated mechanism of action that enables it to potentially address all three key drivers of myelofibrosis: anemia, constitutional symptoms and enlarged spleen. Momelotinib's therapeutic profile targets the underserved myelofibrosis patient population, in particular those with anemia and thrombocytopenia. More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 820 patients treated for myelofibrosis.

Sierra has launched MOMENTUM, a randomized double-blind Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor. The U.S. Food and Drug Administration has granted Fast Track designation to momelotinib. Momelotinib is protected by patents anticipated to provide potential exclusivity to 2040 in the United States and Europe (inclusive of potential Patent Term Extension or Supplementary Protection Certificate).